We report herein the design and synthesis of 17 new spiroheterocycles 10-26, on the basis of two hypothetical pharmacophore structures designed to interact with both of Mycobacterium tuberculosis bacteria and HIV-1 virus. The in vitro biological evaluation of these compounds allowed us to point out seven new potential non-nucleoside hits, with MIC values in the range of 6.25 µg/mL and two new potential anti-HIV-1 inhibitors .
Introduction
Isoxazoline derivatives have been shown to be efficient precursors for many synthetic intermediates including γ-amino alcohols and β-hydroxy ketones.
1-2 Spiro-isoxazolines display interesting biological properties such as herbicidal, plant-growth regulatory and antitumour activities. [3] [4] Many 4-chromanone derivatives are versatile intermediates for the synthesis of natural products such as brazillin, hematoxylin, ripariochromene, clausenin, calonlide A and inophyllum. [5] [6] Chromanone heterocycles have also attracted much attention owing to their important pharmacological properties. 5 Their high synthetic utility and pharmacological importance have prompted us to synthesize and to study the antitubercular activity of some new spiro-isoxazolidine compounds 10-26 (Scheme 1). Previously antitubercular screening of 3-armed imidazo [1,2-a] pyrimidines showed that compounds bearing a formyl, hydroxy or nitroso side chain in position 3 are highly active. [7] [8] From general structure/activity relationship observations, it appears that functionalized side chain(s) such as [X-(C)n-Y], where X,Y = O, N and n = 2 or 3, are crucial for bioactivity. These atoms or centres that have critical interactions with the bacterial cell receptor constitute the pharmacophore and are vital for antimicrobial activities. These interactions must have typically precise geometric requirements that are readily described in terms of the distances between the terminal atoms and their orientation in the pharmacophore sites (O 1 As an extensive continuation of our study on the structure-antibacterial activity relationships in 3-nitroso-imidazo[1,2-a]pyridine (-pyrimidine) derivatives, 8-9b we performed an investigation of spiroheterocycles 10-26 because they represent an attractive model for a theoretical and experimental study of the pharmacophore and their medical applications because of the large variability and combination in their substituents (R 1 and R 2 ). Moreover, given the current interest in selective drugs through the development of molecules that recognize simultaneously specific tuberculosis and HIV-1 sites, we became interested in the combined synthesis, antitubercular and anti-HIV screenings of spiroheterocycles having two rigid pharmacophore systems (O=C-C-O and O-C-O-N) as it was postulated in Figure 3 . The main interesting tasks of this work were: (i) Develop robust prediction models for the heterocycles/ Mycobacterium tuberculosis inhibitory properties (solubility, MT inhibition,
Results and Discussion
Chemistry 1,3-Dipolar cycloaddition reaction of p-substituted-benzaldoximes (1-5) (with (3Z)-3-(4-methylbenzylidene)-1H-isothiochromen-4(3H)-ones (6-9) in biphasic medium of sodium hypochloride and chloroform (NaOCl/ H 2 O/ CHCl 3 ) has been demonstrated to be a powerful and optimal method for the cycloadduct heterocyclic family; 3',4'-diphenyl-4'Hspiro[isothiochromene-3,5'-isoxazol]-4(1H)-ones 10-26 (Scheme 1).
All compounds were characterized using 1 spectroscopy. The selective NMR data are regrouped in Tables 1 and 2 . The isothiochromanone moiety consists of a benzene ring fused with a six-membered heterocyclic ring which adopts a sofa conformation. The five-membered spiro-isoxazoline ring is in the same plan of the phenyl ring. But the p-R 1 -phenyl and p-R 2 -phenyl rings bridged by the five-membered ring are nearly perpendicular to each other ( Figure 3 ).
ARKAT USA, Inc. The (X---Y) distance length of most significant pharmacophore site to inhibit Mycobacterium tuberculosis is probably (O 1 -C 2 -S 1 ) which possesses the requested geometrical parameters and alternative charges (Table 3) . The molecules with the activity contain two substituted phenyl groups on each of the C 3 ' and C 4' atoms of the semi-conjugated isoxazoline ring. The replacement of the two phenyl groups by para-R 1 -phenyl and para-R 2 -phenyl in compound 10 or para-R 1 -phenyl in 15 results in a drastic change of antitubercular activity (from 23 to 91 %inhib.). The increase in activity could be due to the increase of the hydrophobic character that the alkyl and alkyloxy groups confer on the molecule. Hydrophobic molecules with rigid, planar structures such as aromatic rings, have been shown to have the ability to insert into membranes and induce localized permeability changes leading to leakage out of the membrane. 15 The combination of methyl and nitro groups (18 and 24) while also hydrophobic and very easily inserted into the membrane, are much less likely to cause disruption of the lipid packing order. That can be explained by possible cell membrane disturbances as the nitro group is too small to have this type of effect. The enhanced antitubercular inhibition observed in the presence of (15, 16, 17, 19, 21, 22 and 24) is then more likely due to its interaction with some intracellular target. The presence of a strong or poor electron-withdrawing group must alter the nature of the compound in such a way as to promote binding to the target(s).
Evaluation of anti-HIV-1 activity in vitro
As shown in Table 4 , two of these spiranic compounds show anti-HIV-1 activity. In this series however, neither the degree of lipophilicity (cLogP) nor the molecular polar surface area (TSPA) correlates positively with the anti-HIV-1 activity. These parameters were computed using AM1 geometries optimised using the GAUSSIAN03 package, 22 for which more information can be found elsewhere. 23 Interestingly, 25-26 that has NO 2 groups has a smaller Log P value and a very high hydration and TPSA value (of 95 compared to 47.7). These are also the most active species, and should be related to these properties. Although, no relationship was obtained we can suggest that high Log P and hydration energies will lead to active molecules.
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Page 28 A comparison of compounds with regard to their in vitro activity against HIV-1 reveals specificity notably when R1 is nitro substituent. Compounds 25 and 26 have 11 micromolar activity against HIV-1 while others have no activity against HIV-1. It appears that in this limited series, the presence of a more polar substituent on the phenyl of oxazoline ring (compound 25 and 26) enhances the activity (Table 5) .
OSIRIS Calculations
The OSIRIS Property Explorer used in this paper is an integral part of Actelion's inhouse substance registration system. It lets you draw chemical structures and calculates on-the-fly various drug-relevant properties whenever a structure is valid. Prediction results of compounds 10-26 molecular properties (solubility, druglikness and drug-score) are abstracted (Table 6) .
Properties with high risks of undesired effects like mutagenicity or a poor intestinal absorption are shown in red. Whereas a green color indicates drug-conform behaviour.
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Molinspiration calculations cLogP (octanol/water partition coefficient) is calculated by the methodology developed by
Molinspiration as a sum of fragment-based contributions and correction factors. The method is very robust and is able to process practically all organic, and most organometallic molecules. Molecular Polar Surface Area TPSA is calculated based on the methodology published by Ertl et al. 18 as a sum of fragment contributions. O-and N-centered polar fragments are considered.
PSA has been shown to be a very good descriptor characterizing drug absorption, including intestinal absorption, bioavailability, Caco-2 permeability and blood-brain barrier penetration. 18 Prediction results of compounds 10-26 molecular properties (TPSA, GPCR ligand and ICM) are valued (Table 7) . The 3',4'-di-unsubstituted-aryl spiro-isoxazoline compound 10 is among the least active substances to have been evaluated as antituberculosis agents in this series. Accordingly, an effort was initiated to establish a pharmacophore hypothesis to delineate the requirements of the active site via a comprehensive program of analogue synthesis and evaluation of the effects of structural modification(s) on anti-tuberculosis activity of 10.
We then set out to determine the resultant in vitro and in vivo effects of chemical alterations in each region. The unsubstituted phenyl-rings of 10 endowed anti-tuberculosis activity. The modulating anti-tuberculosis effect(s) of substituents having different electronegative properties, located at the para-phenyls sites comprising the two phenyl-rings of region III, were ascertained next. A chloro substituent located at the 4-position on the phenyl ring of 24 generated higher anti-tuberculosis activity relative to 26 and 10 in the Alamar test. However, in general p-nitrophenyl or p-methoxy-phenyl proved to be unhelpful as substituents R 2 . We postulate that the strong tendency to form a (O=C-C-O) dipolar pharmacophore site in the predominant (ketooxnium) form is likely to be responsible for the lack of biological activity observed with these semi π-conjugated isoxazoline derivatives. If this hypothesis is correct, by modifications of 10 we may be able to modulate the degree of interaction of the compound with Mycobacterium tuberculosis bacteria. ). 
General synthesis

Synthesis of 3',4'-diaryl-4'H-spiro[isothiochromene-3,5'-isoxazol]-4(1H)-ones (10-26)
In an erlenmeyer equipped with a bulb for addition, a mixture of 10 mmol of the 3-arylideneisothiochroman-4-one 1-5 and 12 mmol of oxime 6-9 in 20 ml of chloroform was placed in a ice-salt bath, and under magnetic agitation 10 ml of a sodium hypochlorite solution (NaOCl, 18°) was added. Agitation was maintained for one hour after the addition. The organic phase was separated, washed several times with water, and dried on sodium sulphate. The residue obtained after evaporation of the solvent was recrystallized from ethanol. 
3',4'-Di-phenyl-4'H-spiro[isothiochromene-3,5'-isoxazol]-4(1H)-one (10
